Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TYMS | P04818 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | PRF1 | P14222 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2197790 | 1.00 | GRM5 (0.35) | GRM5KCNJ1CYP3A4ALOX5MAOA | |
| SCHEMBL2198745 | 1.00 | GRM5 (0.35) | GRM5KCNJ1CYP3A4ALOX5MAOA | |
| SCHEMBL29957001 | 0.78 | KCNJ1 (0.42) | GRM5KCNJ1ALOX5MAOAMAOB | |
| SCHEMBL2197606 | 0.78 | KCNJ1 (0.42) | GRM5KCNJ1ALOX5MAOAMAOB | |
| SCHEMBL2200762 | 0.76 | MAOA (0.36) | GRM5KCNJ1MAOAMAOBLMNA | |
| SCHEMBL12225662 | 0.71 | MEN1 (0.37) | MAPT | |
| SCHEMBL2200469 | 0.71 | MEN1 (0.37) | MAPT | |
| SCHEMBL2200472 | 0.71 | MEN1 (0.37) | MAPT | |
| SCHEMBL2198651 | 0.71 | CYP2C19 (0.46) | KCNJ1CYP3A4MAOAMAOBLMNA | |
| SCHEMBL2197769 | 0.71 | KCNH2 (0.33) | GRM5KCNJ1CYP3A4ALOX5MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455535-B2 | Heteroaryl dihydroindolones as kinase inhibitors | ALLERGAN, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455535-B2 | Heteroaryl dihydroindolones as kinase inhibitors | ALLERGAN, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455535-B2 | Heteroaryl dihydroindolones as kinase inhibitors | ALLERGAN, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110257238-A1 | Heteroaryl Dihydroindolones as Kinase Inhibitors | ALLERGAN, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257238-A1 | Heteroaryl Dihydroindolones as Kinase Inhibitors | ALLERGAN, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257238-A1 | Heteroaryl Dihydroindolones as Kinase Inhibitors | ALLERGAN, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-7977351-B2 | Heteroaryl dihydroindolones as kinase inhibitors | ALLERGAN, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977351-B2 | Heteroaryl dihydroindolones as kinase inhibitors | ALLERGAN, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977351-B2 | Heteroaryl dihydroindolones as kinase inhibitors | ALLERGAN, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20080045526-A1 | HETEROARYL DIHYDROINDOLONES AS KINASE INHIBITORS | ALLERGAN, INC. | 2008-02-21 | — | — | US | disclosed |
| US-20080045526-A1 | HETEROARYL DIHYDROINDOLONES AS KINASE INHIBITORS | ALLERGAN, INC. | 2008-02-21 | — | — | US | disclosed |
| US-20080045526-A1 | HETEROARYL DIHYDROINDOLONES AS KINASE INHIBITORS | ALLERGAN, INC. | 2008-02-21 | — | — | US | disclosed |
| WO-2007109596-A2 | HETEROARYL DIHYDROINDOLONES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257238-A1 | Heteroaryl Dihydroindolones as Kinase Inhibitors | REN, JAK2, ABL1 | GRM5 2663/4885KCNJ1 2909/4885CYP3A4 1967/4885 |
| US-20080045526-A1 | HETEROARYL DIHYDROINDOLONES AS KINASE INHIBITORS | REN, JAK2, ABL1 | GRM5 2663/4885KCNJ1 2909/4885CYP3A4 1967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.